Nirmatrelvir-Ritonavir Drug Interactions Lead to Multi-Organ Dysfunction in a Lung Transplant Recipient
Introduction: Nirmatrelvir-ritonavir (Paxlovid) therapy for treatment of mild to moderate COVID-19 in lung transplant patients can interact with tacrolimus leading to drug toxicity and organ damage. The appropriate use of Paxlovid in this patient population is of paramount importance.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , M. Pon, W. Zaidi, R. Lee, D. Razia, A. Arjuna Source Type: research
More News: Cardiology | COVID-19 | Heart | Heart Transplant | Lung Transplant | Norvir | Prograf | Tacrolimus | Toxicology | Transplant Surgery | Transplants